分次调强放疗治疗垂体生长激素腺瘤的疗效与预测因素
本研究回顾性分析113例垂体生长激素腺瘤患者接受分次调强放疗(IMRT)的结果,中位随访36个月,内分泌完全缓解率1年6%、2年22.8%、3年48.6%、5年74.3%,肿瘤控制率99%,放疗诱发垂体功能减退总发生率28.3%,放疗前肿瘤大小、IGF-1水平和年龄是内分泌缓解的显著预测因素。
要点
- IMRT对垂体生长激素腺瘤有效,5年内分泌缓解率74.3%,肿瘤控制率99%。
- 放疗诱发垂体功能减退发生率为28.3%,需长期监测。
- 放疗前肿瘤大小、IGF-1水平和年龄可预测内分泌缓解。
核心结论
- IMRT是垂体生长激素腺瘤的高效治疗方法,内分泌缓解率、肿瘤控制率、中位缓解时间和垂体功能减退发生率与立体定向放射外科相似。
- 放疗前年龄和IGF-1水平是内分泌缓解的显著预测因素。
研究设计与样本
- 回顾性研究,纳入2009年8月至2019年1月在本机构接受IMRT的垂体生长激素腺瘤患者113例(男性37例),中位年龄33岁(范围12-67岁)。
- 112例术后未达完全缓解,1例拒绝手术仅接受放疗;放疗前中位生长激素水平8.6 ng/mL(范围2-186 ng/mL),中位IGF-1水平732 ng/mL(范围314-1485 ng/mL)。
- 临床靶区剂量通常为50-56 Gy分25-30次,大体肿瘤体积剂量为60.2 Gy分28次(同步整合推量IMRT时);放疗后每6-12个月内分泌检查,每年磁共振成像。
- 内分泌完全缓解定义为性别和年龄调整的IGF-1水平正常且未使用任何垂体抑制药物;中位随访时间36个月(范围6-105.5个月)。
主要发现
- IGF-1内分泌完全缓解率在1、2、3、5年分别为6%、22.8%、48.6%、74.3%。
- 中位完全缓解时间为36.2 ± 3.8个月。
- 随访期间肿瘤控制率为99%。
- 放疗诱发垂体功能减退总体发生率为28.3%(末次随访时)。
- 单因素和多因素分析显示放疗前肿瘤大小、放疗前IGF-1水平和年龄显著预测内分泌缓解。
关键数值与推荐
- 内分泌完全缓解定义为性别和年龄调整的IGF-1水平正常且未使用任何垂体抑制药物。
- 临床靶区剂量通常为50-56 Gy分25-30次,大体肿瘤体积剂量为60.2 Gy分28次(同步整合推量IMRT时)。
临床怎么用
- 对于术后未达完全缓解的垂体生长激素腺瘤患者,IMRT是可考虑的有效治疗选择。
- 放疗后需每6-12个月进行内分泌检查、每年磁共振成像,监测内分泌缓解和垂体功能减退。
- 放疗前肿瘤大小、IGF-1水平和年龄可帮助预测内分泌缓解概率。
局限性
- 本研究为单中心回顾性研究,样本量113例,中位随访36个月,部分患者随访时间较短。
- 未报告对照组或与其他放疗方式的直接比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To summarize our experience in the treatment of pituitary somatotroph adenomas by fractionated intensity-modulated radiotherapy (IMRT), describe the treatment outcomes, and determine predictors. METHODS AND MATERIALS: Patients with pituitary somatotroph adenoma treated by IMRT in our institution from August 2009 to January 2019 were reviewed. A total of 113 patients (37 male) were included in this study. The median age was 33 years (range 12-67 years). A total of 112 patients had not achieved complete remission after surgery, and 1 patient was treated by radiotherapy (RT) alone because she refused to surgery. The median growth hormone level was 8.6 ng/mL (range 2-186 ng/mL) and the median insulin-like growth factor (IGF)-1 level was 732 ng/mL (range 314-1485 ng/mL) pre-RT. The radiation doses to clinical target volume were usually 50-56 Gy in 25 to 30 fractions and to gross tumor volume were 60.2 Gy in 28 fractions while simultaneous integrated boost-IMRT used. After RT, the patients were followed up with endocrine testing every 6 to 12 months and magnetic resonance imaging annually. Endocrine complete remission was defined as a normal sex- and age-adjusted IGF-1 level without any pituitary suppressive medications. The outcomes including endocrine remission and new hypopituitarism after RT were recorded. The median follow-up time was 36 months (range 6-105.5 months). RESULTS: The endocrine complete remission rates of IGF-1 at 1, 2, 3, and 5 years were 6%, 22.8%, 48.6%, and 74.3%, respectively. The median time to complete remission was 36.2 ± 3.8 months. The tumor control rate was 99% during the follow-up. The overall incidence of RT-induced hypopituitarism was 28.3% at the last follow-up. Univariate and multivariate analysis demonstrated that tumor sizes before RT, pre-RT IGF-1 level, and age significant predicted the endocrine remission. CONCLUSIONS: IMRT is a highly effective treatment for pituitary somatotroph adenoma. Endocrine remission rate, tumor control rate, the median time to remission and hypopituitarism incidence are similar to stereotactic radiosurgery. Age and IGF-1 level before RT were significant predictive factors in endocrine remission.
引用
- Lian X, Shen J, Gu Z, et al. Intensity-modulated Radiotherapy for Pituitary Somatotroph Adenomas. J Clin Endocrinol Metab. 2020. PMID: 32930785. doi:10.1210/clinem/dgaa651
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。